SOURCE: Equity News Circuit

Equity News Circuit

November 12, 2012 08:45 ET

Free Research Reports on ISIS, LGF, MCP and SCLN Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Nov 12, 2012) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) has a broad pipeline consisting of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Shares of the company surged the most in nearly 5 years after Cowen & Co. analyst Eric Schmidt raised its rating to "outperform."

Find out more about ISIS Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ISIS

Lions Gate Entertainment Corp. (NYSE: LGF) shares of the entertainment company spiked 14.25 percent on over 6 times the average daily volume Friday. The company swung to a profit in the fiscal second quarter as revenues were driven by strong ticket sales from several feature films, and "The Hunger Games" home release.

Find out more about Lions Gate Entertainment including full access to the free equity report at: www.BedfordReport.com/LGF

Molycorp Inc. (NYSE: MCP) shares of the rare earth processor fell sharply Friday on over 5 times the average daily Volume. The company has reported that it is being investigated by the SEC over the accuracy of their disclosures.

Find out more about Molycorp including full access to the free equity report at: www.BedfordReport.com/MCP

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a specialty pharmaceutical company with a substantial commercial business in China and a diverse product portfolio. Shares of the company fell sharply last Friday after reporting disappointing third quarter results.

Find out more about SciClone Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/SCLN

Disclaimer: Equity News Circuit is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, bedfordreport.com has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.

Contact Information